Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE

2 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE
Treatment and conditionWhere it standsTrials
Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for liposarcoma, myxoidPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Letetresgene autoleucel (lete-cel, GSK3377794) + Cyclophosphamide + FLUDARABINE for sarcoma, synovialPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1